Quick Answer: What Does Stage 4 Prostate Cancer Mean?
Stage 4 prostate cancer is advanced prostate cancer, but Stage IVA and Stage IVB are different diseases clinically and should not be treated as though they have the same prognosis.
- Stage IVA: prostate cancer has reached regional pelvic lymph nodes but there are no distant metastases (N1, M0).
- Stage IVB: cancer has spread to distant lymph nodes, bones or other organs (M1).
- Stage IVA disease can still be treated aggressively with long-term cancer control—and sometimes cure—as the goal in appropriately selected patients.
- Newly diagnosed metastatic Stage IVB disease is usually treated with androgen-deprivation therapy (ADT) plus additional systemic treatment, rather than ADT alone in a fit patient.
- Treatment may include abiraterone, apalutamide, enzalutamide or other androgen-receptor pathway therapy, and selected patients may also receive docetaxel chemotherapy.
- There is no reliable single “life expectancy” such as 8 or 9 years. Prognosis varies enormously according to metastatic burden, cancer biology, treatment response and general health.
What Is Stage 4 Prostate Cancer?
Prostate cancer staging describes how far the cancer has spread when it is diagnosed.
Doctors use the TNM system:
- T describes the primary prostate tumor;
- N describes whether regional lymph nodes contain cancer;
- M describes whether cancer has spread to distant parts of the body.
PSA and Grade Group also contribute to prostate-cancer stage grouping.
Stage IVA vs Stage IVB Prostate Cancer
| Stage | TNM Pattern | What It Means | General Treatment Approach |
|---|---|---|---|
| Stage IVA | Any T, N1, M0 | Cancer is present in regional pelvic lymph nodes but there is no distant metastasis. | Often intensive treatment involving radiotherapy plus long-term ADT and additional systemic therapy in suitable patients. |
| Stage IVB | Any T, any N, M1 | Cancer has spread beyond regional nodes to distant lymph nodes, bones or other organs. | Systemic treatment is central; additional prostate or metastasis-directed treatment may be appropriate in selected situations. |
This distinction is extremely important when discussing treatment, prognosis and survival.
Where Does Metastatic Prostate Cancer Commonly Spread?
Prostate cancer can spread to several sites.
The most important include:
- bones;
- distant lymph nodes;
- lungs;
- liver;
- and, less commonly, other organs.
Bone is a particularly common site of metastatic prostate cancer.
Metastatic burden also matters. A man with only a few metastatic deposits may be managed differently from a man with extensive bone and visceral disease.
What Are the Symptoms of Stage 4 Prostate Cancer?
Some men have surprisingly few symptoms when advanced disease is first detected.
Others may experience symptoms related either to the prostate itself or to metastatic disease.
Urinary Symptoms
- difficulty starting urination;
- weak urine flow;
- incomplete bladder emptying;
- urinary frequency or urgency;
- blood in urine;
- or urinary retention.
These symptoms are not specific to cancer. They can also occur with benign prostatic hyperplasia (BPH) and other urinary conditions.
Symptoms From Bone Metastases
- persistent back, hip or pelvic pain;
- rib or other bone pain;
- bone fractures;
- reduced mobility;
- or spinal-cord compression.
General Symptoms
Advanced disease may also cause:
- fatigue;
- loss of appetite;
- unintentional weight loss;
- anemia;
- weakness;
- or leg swelling when lymphatic drainage is affected.
How Is Stage 4 Prostate Cancer Diagnosed and Staged?
No single test establishes the complete picture.
Evaluation may include:
- PSA testing ;
- prostate biopsy and Grade Group;
- multiparametric prostate MRI;
- CT or MRI of the abdomen and pelvis;
- bone imaging;
- and increasingly PSMA PET/CT when appropriate and available.
Imaging is used not only to confirm whether cancer has spread but also to estimate the volume and distribution of metastatic disease.
How Is Stage IVA Prostate Cancer Treated?
Stage IVA prostate cancer with regional lymph-node involvement but no distant metastases is usually approached differently from metastatic Stage IVB cancer.
Current European guidance recommends, for suitable cN1 M0 patients:
- radiotherapy to the prostate and pelvis;
- long-term androgen-deprivation therapy (ADT);
- and two years of abiraterone in appropriate patients.
Selected patients may be considered for other multimodal approaches in specialist centers, but management should be discussed within a multidisciplinary prostate-cancer team.
Stage IVA Is Not Automatically an Incurable Situation
Regional lymph-node disease without distant metastasis can still be treated aggressively with long-term disease control—and potentially cure—as the treatment goal in appropriately selected patients.
How Is Metastatic Stage IVB Prostate Cancer Treated?
Treatment of Stage IVB prostate cancer depends first on whether the cancer is still hormone-sensitive or has become castration-resistant.
Androgen-Deprivation Therapy
Prostate cancer cells usually depend heavily on androgen signaling.
ADT lowers testosterone or blocks its production and remains the foundation of treatment for metastatic prostate cancer.
ADT can be achieved using:
- LHRH/GnRH agonist medicines;
- GnRH antagonist medicines;
- or surgical removal of the testicles (orchiectomy), used much less frequently in many countries.
ADT Alone Is Usually No Longer Enough for a Fit Patient
One of the major advances in prostate-cancer treatment is the recognition that most fit men with newly diagnosed metastatic hormone-sensitive prostate cancer benefit from adding another treatment to ADT.
Common options include ADT combined with an ARPI such as:
- abiraterone plus prednisone/prednisolone;
- apalutamide;
- enzalutamide;
- or another appropriate modern androgen-receptor pathway treatment.
These combinations have improved outcomes compared with traditional ADT alone.
When Is Chemotherapy Added?
Docetaxel chemotherapy can be useful in selected men with newly diagnosed metastatic disease.
Modern treatment increasingly uses docetaxel as part of triplet therapy rather than simply adding docetaxel to ADT alone.
Examples include:
- ADT + docetaxel + abiraterone;
- or ADT + docetaxel + darolutamide.
Triplet therapy is particularly considered in suitable patients with newly diagnosed high-volume or high-risk metastatic disease.
Whether chemotherapy is appropriate depends on:
- age and physical fitness;
- heart, kidney and liver function;
- other medical conditions;
- extent of metastases;
- previous therapy;
- and patient preferences.
Does Radiation Have a Role in Stage 4 Prostate Cancer?
Yes, but the purpose depends on the disease pattern.
Low-Volume Newly Diagnosed Metastatic Disease
An important modern development is prostate-directed radiotherapy for selected men whose first diagnosis is metastatic but whose metastatic burden remains low.
Current EAU guidance strongly recommends combining ADT with prostate radiotherapy for men presenting with M1 disease who meet low-volume criteria.
This is based in part on STAMPEDE data showing a survival benefit in the low-volume subgroup.
Palliative Radiation
Radiation is also extremely useful for treating symptoms from metastatic sites—for example:
- painful bone metastases;
- threatened fractures;
- spinal metastases;
- or other troublesome localized cancer deposits.
Is Radical Prostatectomy Used for Stage 4 Prostate Cancer?
This requires another correction from the older version of this article.
Radical prostatectomy is not standard treatment for metastatic M1 prostate cancer.
Current EAU guidance recommends against combining ADT with prostate surgery for M1 disease outside clinical trials.
Surgery may occasionally have a role in carefully selected node-positive nonmetastatic patients as part of multimodal management, but this is quite different from routinely operating on Stage IVB metastatic cancer.
TRUS Is Not a Prostate-Cancer Operation
The older article referred to “TRUS” as though it were a surgical treatment. TRUS means transrectal ultrasound and is an imaging technique, not an operation for metastatic prostate cancer.
What About Brachytherapy?
Brachytherapy uses radioactive sources placed in or near the prostate.
It should not be described as placing a “chemical” into the prostate.
Brachytherapy has important roles in selected localized and locally-advanced treatment strategies, but it is not a routine stand-alone treatment for widely metastatic Stage IVB disease.
Treatment in metastatic prostate cancer is primarily systemic, with radiation used selectively according to metastatic burden and symptoms.
What If Stage 4 Cancer Stops Responding to Initial Hormone Therapy?
Prostate cancer that continues to progress despite testosterone being suppressed to castrate levels is called castration-resistant prostate cancer (CRPC).
Metastatic CRPC is not the end of treatment options.
Depending on previous therapy, symptoms and molecular findings, treatment may include:
- docetaxel;
- cabazitaxel;
- appropriate androgen-receptor pathway treatments;
- PARP-targeted treatment in selected cancers with relevant DNA-repair mutations;
- radioligand therapy such as lutetium-177–PSMA in appropriate patients;
- radium-223 for selected patients with symptomatic bone-predominant disease;
- and clinical trials.
Treatment sequencing has become increasingly individualized.
Why Is Genetic Testing Important in Metastatic Prostate Cancer?
Modern advanced-prostate-cancer care increasingly includes molecular testing.
Current EAU guidance recommends testing metastatic patients for homologous-recombination repair abnormalities because mutations involving genes such as BRCA1 or BRCA2 can influence treatment options.
Testing may involve:
- tumor genomic testing;
- blood-based testing when appropriate;
- and germline testing for inherited variants in selected patients.
How Are Bone Metastases Managed?
Bone metastases are common in advanced prostate cancer and deserve specific attention.
Management may include:
- effective systemic cancer therapy;
- pain medication;
- targeted radiotherapy to painful areas;
- orthopedic assessment when a fracture is threatened;
- calcium and vitamin D assessment where appropriate;
- bone-density monitoring during long-term ADT;
- and bone-targeted medicines in selected clinical circumstances.
Treatment should consider both cancer-related bone damage and osteoporosis that can result from prolonged androgen deprivation.
Does Palliative Care Mean Treatment Has Stopped?
No.
Palliative care can be provided at the same time as active cancer treatment.
Its purpose is to help control:
- pain;
- fatigue;
- urinary symptoms;
- treatment side effects;
- sleep problems;
- emotional distress;
- and other quality-of-life concerns.
Early supportive care can be an important part of comprehensive treatment for advanced cancer.
Stage 4 Prostate Cancer Life Expectancy and Survival
This is one of the most difficult questions patients and families ask, and it deserves careful wording.
There is no medically defensible statement that the average Stage 4 patient lives exactly 8, 9 or 10 years.
The American Cancer Society currently reports a 5-year relative survival rate of about 38% for men whose prostate cancer is classified as distant stage in the SEER database.
38% Does Not Mean “You Have a 38% Chance of Living Five Years”
Population statistics cannot predict an individual patient’s outcome.
These statistics are also based on men diagnosed between 2015 and 2021, so they do not fully capture the benefits of every treatment now available in 2026.
SEER also uses localized, regional and distant categories, not the exact AJCC Stage IVA/IVB grouping.
Therefore, the 38% statistic should not be applied to a patient whose disease is Stage IVA because of regional lymph nodes only.
What Determines the Prognosis?
Important factors include:
- Stage IVA versus IVB;
- number and location of metastases;
- low-volume versus high-volume metastatic disease;
- bone-only versus visceral metastases;
- Grade Group;
- PSA and PSA response to treatment;
- whether disease is hormone-sensitive or castration-resistant;
- genomic features such as BRCA/HRR alterations;
- overall health and fitness;
- response to initial treatment;
- and availability of subsequent therapies.
Stage 4 Prostate Cancer Is Increasingly Treatable
Metastatic prostate cancer is generally not considered curable with current standard therapy, but many patients can have the disease controlled for meaningful periods, and treatment options have expanded substantially over the last decade.
Symptoms That Need Urgent Medical Attention
Some complications of advanced prostate cancer require immediate assessment.
Seek urgent medical care for:
- new severe back pain with leg weakness or numbness;
- difficulty walking associated with new back pain;
- new loss of bladder or bowel control;
- numbness around the buttocks, genital region or inner thighs;
- sudden severe bone pain or suspected fracture;
- complete inability to urinate;
- or severe illness with rapidly worsening symptoms.
New neurological symptoms in a patient with prostate cancer can indicate metastatic spinal-cord compression, which is an oncological emergency.
Dr. Albana’s Perspective
When someone tells me that he has Stage 4 prostate cancer, the first thing I want to know is whether this means Stage IVA or Stage IVB.
Stage IVA may mean that cancer has reached regional pelvic lymph nodes but has not spread to distant organs. That can still be approached aggressively in suitable patients.
Stage IVB means distant metastatic disease. In that situation, systemic treatment becomes the foundation of care.
Another major change from older prostate-cancer treatment is that we no longer generally rely on androgen-deprivation therapy alone for a fit man presenting with metastatic hormone-sensitive disease. Modern treatment usually combines ADT with another effective systemic therapy, and some patients benefit from triplet treatment including chemotherapy.
I would also not tell a patient that he has an “average life expectancy of eight or nine years.” Survival statistics describe populations, not individual patients, and today’s prognosis depends heavily on disease burden, biology and response to increasingly effective treatments.
For an individual patient, the most useful information is the complete staging report, Grade Group, PSA, imaging—including metastatic sites—and the treatment-response pattern.
— Dr. Albana Greca, MD, MMedSc, Family Physician / General Practitioner
Most Asked Questions About Stage 4 Prostate Cancer
Is all Stage 4 prostate cancer metastatic?
Not in the sense of distant metastasis. Stage IVA means regional lymph-node involvement without distant metastases. Stage IVB means distant metastatic disease.
Can Stage 4 prostate cancer be cured?
Some Stage IVA patients with regional lymph-node disease can be treated aggressively with cure or very long-term control as the goal. Widely metastatic Stage IVB disease is generally considered treatable but not curable with current standard therapy.
What is the first treatment for metastatic prostate cancer?
Androgen-deprivation therapy remains the foundation, but fit men with newly diagnosed metastatic hormone-sensitive prostate cancer generally receive treatment intensification with an androgen-receptor pathway inhibitor, with chemotherapy added for selected patients.
Is watchful waiting the first treatment for Stage 4 prostate cancer?
No. Watchful waiting may be appropriate for selected frail patients or those with limited life expectancy, but it is not the standard first-line strategy for a fit patient with newly diagnosed metastatic disease.
Can Stage 4 prostate cancer spread to bones?
Yes. Bone is one of the most common sites of distant prostate-cancer metastasis.
Can radiation be used when prostate cancer has already spread?
Yes. Prostate radiotherapy is recommended for selected men with newly diagnosed low-volume metastatic disease, and radiation can also be used to relieve pain or control individual metastatic sites.
Is surgery used for metastatic Stage IVB prostate cancer?
Radical prostatectomy is not standard treatment for M1 metastatic disease. Current EAU guidance recommends against combining ADT and surgery for M1 disease outside clinical trials.
What happens when hormone therapy stops working?
The disease is described as castration-resistant when it progresses despite appropriately suppressed testosterone. Multiple additional therapies remain available, including chemotherapy, targeted treatment for selected mutations, radioligand therapy and other systemic therapies.
What is the 5-year survival rate for metastatic prostate cancer?
Current American Cancer Society data report approximately 38% 5-year relative survival for distant-stage prostate cancer diagnosed from 2015–2021. This population statistic cannot predict the outcome of an individual patient and does not directly represent Stage IVA disease.
Related Prostate Cancer Guides
Medical References
-
European Association of Urology.
EAU Guidelines on Prostate Cancer — Treatment.
2026.
EAU Prostate Cancer Treatment Guideline -
European Association of Urology.
EAU Guidelines on Prostate Cancer — Classification and Staging
Systems.
2026.
EAU Classification & Staging -
National Cancer Institute.
Prostate Cancer Treatment (PDQ®) — Health Professional Version.
National Cancer Institute -
National Cancer Institute.
Prostate Cancer Treatment (PDQ®) — Patient Version.
NCI Patient Information -
American Cancer Society.
Survival Rates for Prostate Cancer.
Revised January 13, 2026.
American Cancer Society -
American Cancer Society.
Initial Treatment of Prostate Cancer, by Stage and Risk Group.
American Cancer Society
Medical information notice: Stage 4 prostate cancer requires individualized specialist care. Treatment depends on Stage IVA versus IVB, metastatic burden, Grade Group, PSA, previous treatment, molecular findings, symptoms and general health. Specific treatment decisions should be made with the treating urologist and medical/radiation oncology team.
Written & medically reviewed by Dr. Albana Greca, MD, MMedSc • Family Physician / General Practitioner • Last medically reviewed: August 2026